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Histamine has a positive inotropic action in humans. Recent
controversial data have suggested that histamine s (H s ) receptor
blockade depresses overall left ventricular systolic performance in
healthy volunteers. To explore the possibility that H, receptors
positively influence basal left ventricular contractile tone, 10
normal subjects were studied by using imaging and Doppler
echocardiography and calibrated subelavian pulse data in a
blinded, randomized, two-period crossover trial with measure •
meets obtained at the end of each 7-day period .
Oral drug administration consisted of either the potent H,
antagonist famotidine (40 mg/day) or placebo. Left ventricular
circumferential end-systolic wall stress-rate-corrected velocity of
fiber shortening (Vcf) relations were generated over a range of
loads with metboxamine
. Contractility was assessed by using Ver,
at a common end-systolic wall stress. During each study, data
Studies (1-5) performed in animals and humans have sug-
gested that histamines (H,) receptors exist in the myocar-
dium and peripheral blood vessels . Stimulation of these
receptors activates adenylate cyclase, thereby increasing the
intracellular concentration of cyclic adenosine monophos-
phate (AMP), which results in increases in left ventricular
muscle tension and contractility (2-5) . In patients with
severe left ventricular dysfunction refractory to dobutamine,
impromidine, a specific H, receptor agonist, has been shown
(6,7) to increase cardiac output and decrease pulmonary
capillary wedge pressure . H2-blockers selectively inhibit the
binding of histamine to H2 receptors (2,5), thereby reducing
intracellular concentrations of cyclic AMP . Because agents
such as cimetidine (Tagamet), ranitidine (Zantac) and famo-
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were obtained before and during high dose intravenous esnmlol
administration to determine the contributions, if any, of sympa-
thetic reflex responses .
Famotidine did not alter blood pressure, left ventricular
percent fractional shortening, circumferential end-systolic wall
stress, stroke volume index, cardiac index, total vascular resis .
tance or ventricular contractile state in comparison with placebo
but did decrease heart rate by 3 heaWmin (p < 0 .05). With
beta•adrenergie blockade, no difercm~s in contractility were
evident between esmolol alone and famotidine pies esmold,
Thus, Hs receptor blockade with fmotidine does not alter
myocardial mechanics or cardiac sympathetic tone, suggesting
that in humans basal leh, ventricular contractile stale is not
physiologically dependent on the Hystediated effects of histamine,
(J Am Can Ca diet 1"2;19.1229-36)
tidine (Pepcid) are an integral part of the clinical treatment of
active peptic ulcer disease (5,8,9), it is pertinent to determine
whether a potent H2 antagonist adversely affects contractile
stale.
Famotidine, which on a weight basis is 8 times more
potent than ranitidine and 40 times more potent than cimet-
idine and has a longer duration of action than either of these
drugs, is of particular interest (5,8,9) . Recent studies per-
formed by Kirch, Hinrichsen and coworkers (10,11) in
normal subjects have raised concerns regvrding the possible
adverse effect of famotidine on left ventricular contractility.
Specifically, these investigators (10,1) reported that oral
famotidine (40 mg/day) increased the left ventricular pre-
ejection period to ejection time ratio and decreased ventric-
ular stroke volume by impedance cardiography. They con-
cluded that famotidine has a "significant negative effect on
cardiac performance
." However, other clinical studies (12-
15) have failed to confirm these conclusions . If H9 receptor
blockade with famotidine does indeed depress myocardial
contractile state in humans in the absence of histamine
release from mast and other cells, the implication would be
that ambient blood histamine contributes to basal left ven-
tricular contractile tone . If this were true, new approaches
0735-109719255 .00
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could be opened for the treatment of left ventricular pump
dysfunction because myocardial H2 receptor density is uni-
form and does not appear to be subject to the regulatory
changes that account for the wide variability in beta-receptor
number and density in patients with heart failure (6,7) .
All previous reports on the cardiac effects of famotidine
have been based on measurements of overall left ventricular
performance that are highly dependent on load and heart
rate . In no case was it possible to differentiate changes in left
ventricular contractility from simultaneously occurring
changes in preload and afterload . This is important because
intravenously administered H, blockers have been reported
(13,16) to produce significant changes in peripheral vascular
tone and ventricular loading conditions . Furthermore, the
indirect cardiac effects of reflex sympathetic activation that
may have resulted from treatment with famotidine were not
considered . If these occurred, the drugs direct negative
inotropic effect might have been even greater than reported
previously (10,11). To differentiate between the contribu-
tions of load changes, direct inotropic action and reflex
sympathetic stimulation, a more specific measurement of
contractility
a required. By systematically employing a
series of pharmacologic probes, it is possible with totally
noninvasive tech,liques to assess the inotropic action of a
drug while delineating contributions from the cardiac sym-
pathetic nervous system (17-23).
Using the H 2 receptor antagonist famotidine in conjunc-
tion with the beta-adrenoceptor antagonist esmolol, the
current study attempted to determine whether circulating
histamine has an effect on basal left ventricular contractile
tone and loading conditions in humans .
Methods
Study subjects . Ten normal subjects between the ages of
18 and 50 years with a mean systemic blood pressure
5105 mm Hg, technically adequate echocardiographic im-
ages of the left ventricle and normal overall ventricular
systolic performance (i .e., percent fractional shortening
m28%) were eligible for study . Each subject had normal
results on a rest electrocardiogram (ECG), physical exami-
nation, complete blood count and blood chemistry profile .
Exclusion criteria included I) any contraindication to inges-
tion of an H, antagonist or beta-adrenoceptor blocking
agent, 2) any clinical, ECG or echocardiographic findings
suggestive of coronary artery or valvular heart disease, or
3) significant cardiac rhythm disturbances . The protocol was
approved by the Institutional Review Board of the Univer-
sity of Chicago Medical Center. In all cases, informed
written consent was obtained
.
Study medications . Famotidine (40 mg) and matching
placebo were supplied by Merck Sharp and Dohtse Research
Laboratories
. Patients took one tablet (active d :ssg or pla-
cebo) each morning at approximately 7 AM . The investiga-
tors had no knowledge of the drug randomization sequence
until the termination of data collection, data correction
FemotIdInn Placebo
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Figure 1. Schematic presentation of the experimental design em-
ployed in the current study . Echo = imaging and Doppler echocar-
diography.
and verification and submission of analyzed data to the
external monitor for the investigation . Each subject was
informed of the importance of complying with the study
protocol . Patients were asked to return all unused medica-
tions at each visit and were queried about any missed doses .
The number of tablets dispensed and the number returned
were recorded .
Experimental design . This was a double-blind, random-
ized placebo-controlled, two-period, crossover study involv-
ing 10 normal subjects (Fig. I). During each period, subjects
received by randomized allocation either famotidine (40 mg)
or placebo once daily for I week . Imaging and Doppler
echocardiography and hemodynamic studies were per-
formed at the end of each 7-day treatment period . The dose
of famotidine selected reflects typical clinical recommenda-
tions (5,8,9). Equal numbers of subjects were assigned to the
two treatment sequences by a randomized allocation pre-
pared by the Department of Pharmaceutical Services at the
University of Chicago Medical Center
. Packaging of medi-
cations was performed by the Medical Center's pharmacy .
Study protocol. Each subject was seen on four separate
occasions
: visit 1, screening studies ; visit 2, start of I week
of administration of active drug (or placebo)
; visit 3, imaging
and Doppler echocardiographic study I
followed by start of
I week of administration of placebo (or active drug)
; visit 4,
imaging and Doppler-echocardiographic study 2 and subse-
quent termination of study .
All cardiac ultrasound examinations were performed 2 to
3 h after the dose of famotidine or placebo . This timing for
data acquisition coincides with the previously reported (5)
average time to peak serum concentration after oral inges-
tion of famotidine. Recordings included left ventricular
two-dimensional and targeted M-mode echocardiograms,
continuous wave Doppler velocity tracings of aortic valve
flow, echocardiographically determined aortic annular cross-
sectional area, phonoeardiogram, ECG and indirect subcla-
vian pulse tracing
. Systolic, diastolic and mean aortic blood
pressure determinations were made with the t)inamap 1846
XSP Vital Signs Monitor (Critikon Inc
.). In previous com-
parison studies (24-26), this device was shown to accurately
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estimate central aortic pressures over a wide range of
systolic, diastolic and mean pressures
.
Pharmacologic probes
. After completion of baseline re-
cordings, an intravenous infusion of the specific alpha,-
adrenoceptor agonist methoxamine hydrochloride (0
.5 to
I mg/mia) was begun . Each subject was premeditated with
atropine sulfate (0
.005 to 0 .01 mg/kg body weight) to main-
tain a stable heart rate (i .e ., prevent barereceptor-mediated
reflex bradycardia) . Systolic blood pressure was raised
slowly by 20 to 40 mm Hg above the rest value with
recordings performed every I to 2 min
. After the maximal
desired systolic pressure was reached, the methoxamine
infusion was discontinued
. In general, peak pressure was
maintained for 3 to 4 min and then decreased by an average
of 3 mm Hg/min
. When peak left ventricular systolic pros.
sure returned to within 10% of baseline, repeat recordings
(as outlined earlier) were performed . Each subject was then
given esmolol, an ultrashort-acting cardioselective beta-
atlrenoceptor blocking agent (27,28) . This drug has a very
rapid onset of action . Esmolol was given intravenously as a
500 µg/kg bolus followed by a continuous infusion at
100 jig/kg per min. After 5 to 7 min . a repeat 500 Ag/kg per
min bolus was administered followed by continuous infusion
at 200 gg/kg per min. After >_15 min of high dose drug
infusion, baseline esmolol data were acquired
. We have
previously shown that this dosing regimen yields a z2
.5-fold
beta adrenergic blockade as quantified by isoprotcrenol
challenge
(23) . Finally, with the esmolol infusion maintained
at 200 psg/kg per min, the methoxamine challenge was
repeated .
Analysis ofhemodynamicdata. The timing of end-diastole
was defined as the peak of the R wave on the ECG .
End-systolic measurements were made at the first high
frequency component of aortic valve closure on the phono-
cardiogram . Left ventricular end-diastolic and end-systolic
minor-axis dimensions (Des , Die) as well as wall thicknesses
(hen , hen)
were measured from parastemal targeted M-mode
echocardiographic recordings acquired perpendicular to the
left ventricular long axis and through the midline of short-
axis images. Care was taken to record the largest left
ventricular minor-axis dimensions present between the tips
of the mitral valve leaflets and the superior aspect of the
papillary muscles, This chordal measurement approximates
the mid-equatorial plane of the left ventricle
. Left ventricular
end-diastolic and end-systolic long-axis dimensions (L . .
Lee) were measured from the two-dimensional echocardio-
graphic apical four-chamber view . The apical endocardium
was defined as the point within the left ventricle at which the
septum and lateral wall formed the most acute angle
. This
was accomplished by positioning the transducer as far lateral
or inferior, or both, as necessary . The distance from the
apex to the mid-portion of the mitral valve anulus and the
width of the anulus were simultaneously maximized, thus
avoiding tangential imaging of the left ventricle
.
Cardiac output was determined by multiplying heart rate
and left ventricular stroke volume. The latter was calculated
ROROW ET AL.
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as the product of two-dimensional echographically measured
aortic u,nular cross-sectional area and continuous wave
Doppler ultrasound-determined flow velocity integral ac-
quired through the aortic valve
. Cardiac index and stroke
volume index were calculated by dividing by body surface
area, Total vascular resistance (TVR
; dyncs-s-cm'
S)
was
determined as:
~- -J
TVR-
80) .
cD
where P,v = mean aortic pressure (mm Hg) and CO =
cardiac output (liters/min).
The left ventricular percent fractional shortening (%AD)
was derived as (Dra
- D,,)/D, Left ventricular end-systolic
pressure (P,,)
was determined from linear interpolation to
the height of the incisura by using a calibrated subclavian
pulse tracing
(29) . Left ventricular ejection time (LVET) was
measured from the external pulse tracings in the standard
manner (29)
. The rate-corrected left ventricular mean veloc-
ity of circumferential fiber shortening
(Vcf) was calculated
as (17 .29) :
%AD %AD
Vcf, =
=-(~),
(LVET)1(~) LVET
where RR = the interval between consecutive cardiac cy-
cles.
Left ventricular circumferential wall stress (o1 was calcu-
lated using the equation of Sandler and Dodge (30) as the
product of pressure and a geometric factor that includes
minor- (D) and long- (L) axis dimensions and wall thickness
(h) :
D p3
a`_lpj 2h~1-2L'-(D+h))](1
.33),
where v is in glcm2,
P is in mm Hg, D, L and h are in cry and
1 .35 converts pressure from mm Hg to g/cm
2 .
Assessment of left ventricular contractility
. Left ventricu-
lar contractility was measured by using the load- and heart
rate-independent relation between end-systolic circumferen-
tial wall stress and rate-corrected velocity of fiber shorten-
ing . In each subject, the a,,V
cf relation was determined by
linear regression analysis (least squares method) using a
minimum of four data points acquired over a wide range of
aftertoads (i.e ., circumferential end-systolic stress) gener-
ated during methoxamine infusion
. For each subject, data
were compared for placebo alone, famotidine alone, esmolol
alone and famotidine plus esmolol conditions at a common
value of left ventricular end-systolic wall stress .
The following differences in rate-corrected velocity of
fiber shortening (AVcf,) were determined
: 1) famotidine
minus placebo, reflecting the effect of famotidine on left
ventricular contractile state with a physiologically intact
cardiac sympathetic nervous system ; 2) esmolol minus pla-
cebo, reflecting the inherent negative inotropic effect of
esmolol ; 3) (famotidine plus esmolol) minus famotidine,
1 232
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Figarr 2. Physiologic framework illustrating the effect
of
a hype.
Ihctica! drug or the left veelocularend .systolie circumferential wall
stress (e-J-rate-corrected velocity of fiber shortening (Vcf .) rela-
tion. Comparisons are made with placebo data
. Esmolul (Esm) is
used In pharmacologically ablate the effect of the cardiac sympa-
thetic nervous system. See text for detailed explanation
. Lu =
change.
reflecting the negative innlrnpic notion of esmolol as com-
pared with The combined contractility effect of famotidine
and reflex cardiac sympathetic stimulation
; and 4) )/innn i-
dine plus esmolol) nuns esmolol, reflecting the
effect
of
famotidine alone on left ventricular contractility with the
cardiac sympathetic nervous system eliminated as a con-
founding variable . These concepts are illustrated for a hy-
pothetical drug in Figure 2, which plots left ventricular
afterload with rate-corrected velocity of fiber shortening . If
off, Vef data were similar for drug and placebo when
analyzed at a common level of left ventricular end-systolic
circumferential wall stress, then AM, would be 0 and the
drug would have no net effect on left ventricular contractility
when the cardiac sympathetic nervous system was fully
functional . However, these data do not differentiate between
the lack of a negative inotropic effect of the drug and a
drug-induced depression in left ventricular contractility (hat
was masked by reflex activation of the cardiac sympathetic
nervous system . This distinction can be made by analyzing
the a
; Vcfe values for the drug plus esmolol minus esmolol
data . When this is performed . AM, is noted to he -0.04
circumferencesis . The drug did not appear to have any effect
on left ventricular contractility under baseline conditions,
Only when the sympathetic response was ablated by beta-
adrenoceptor blockade with esmolol was it possible to
demonstrate the drug's true negative inotrapic action .
Slntisdcalanalysis. Each subject served as his other own
control
. The paired r test was used to assess the hemody-
namic changes induced by famotidine and esmolol relative to
their respective placebo values. 'l'he study was designed to
have SOld power to detect a true Vcf, difference of approx-
imately 0 .01
circumference's
Correction for multiple com-
parisons was made by using a Bonferroni factor whereby
significance was accepted as p < 0.05/k, where k = 4
comparisons . Thus, statistical significance was considered
MCC Vv1. 19, Nu . 6
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present at p < 0 .0125 . Group data are expressed as mean
values t SO,
Results
Study subjects . The 10 normal subjects ranged in age
from 20 to 52 years ; 7 were male
. The average body surface
area was 1 .9
t
0 .16 m' with an aortic annular cross-sectional
area of 3 .£4 ± 0.b9
cm'.
All subjects fully complied with the
dosing schedule and successfully completed the treatment
protocol as originally designed . No side effects were re-
ported with famotidine or placebo .
Hernodynarnic Data
The cardiovascular hemodynamic data for the placebo,
famotidine and esmolol conditions are summarized in
Table I .
Heart rare. Compared with placebo, heart rate decreased
by 3 beatsimin with famotidine (p < 0 .05) and by 4 beats(min
with esmolol (p < 0.01). No differences were noted for
famotidine plus esmolol versus either famotidine or esmolol .
Pressures . Esmolul with either placebo or famotidine
minimally raised mean aortic pressure relative to placebo
(p = 0.07) at
-
famotidine (p < 0.05) . No other interdmg
differences were noted for left ventricular peak systolic, left
ventricular end-systolic . aortic diastolic or aortic mean pres-
sures .
Left ventricular preload . This was assessed as left ven-
tricular end-diastolic dimension. Increases tended to occur
with esmelel (p = 0.06 vs. placebol and famotidine plus
esmolol (p < 0 .05 vs. famotidine) . No other interdrug
differences were noted .
Left ventricular aftertoad . Famolidine had no effect on
left ventricular afterload . In contrast, esmolol and famoti-
dine plus esmolol increased total vascular resistance (p <
0 .001) and left ventricular end-systolic circumferential wall
stress (p < 0.01) relative to placebo and famotidine, respec-
tively.
Overall left ventricular systolic performance . Left ventric-
ular end-systolic dimension, percent fractional shortening,
rate-corrected velocity of fiber shortening, stroke volume
index and cardiac index were not statistically different for
placebo and famotidine. Esmolul infusion with either pla-
cebo or famotidine increased end-systolic dimension while
depressing all other measurements of overall left ventricular
performance relative to placebo or famotidine, respectively .
No differences were noted for esmolol versus famotidine
plus esmolol .
Left Ventricular Conirucrifity
Figure 3 shows representative data from one of our study
subjects . Left ventricular end-systolic circumferential wall
stress is plotted with rate-corrected velocity of fiber short-
ening . Each line was generated over a wide range of values
3ACC Vul. 19 . No . 6
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Table 1
. Summary of Hemodynamic Data in
10
Subjects
F
s8 - 6
112 x 9
w v 1 2
MI _ 8
81 ' 8
185
. 0
.36
1 296 ^_ 291
D5 _ 17
3 .-^8 '
11.26
P-.4=27
1,05 8 0 .07
47 x 6
2
.68
0
0.31
Ao = aortic ; BSA = body surface area : CI - cardiac indes: D,a = left ventricular
end-diastolic
dimension: D., = lea ventricular end-systolic dimension ; E
smolol : F = famotidine: LV = left ventricular: F = placebo : C37D = left ventricular percent fractional shortening : v., = IeO venricular end-systolic
circumferential wall stress ; SVI = stroke volume index : TVR = total vascular
resistance:
Vcf, = left ventricular rata-corrected velocity of fiber shortening .
for left ventricular afterload under conditions of famotidine
alone, famotidine plus esmolol, placebo alone and esmolol
alone . For this subject, all Vcf, values were determined at a
level of end-systolic wall stress (i .e . . 188 g/cm) that was
Figure 3. Representative left ventricular end-systolic circumferen-
lial wall stress (oej-rate-corrected velocity of fiber shortening
IVef) relations generated from one study patient . No significant
differences in AVcf were noted when famotidine (F) alone was
compared with placebo IN and when famotidine plus esmolol
(F + E) was compared with esmolol IE) alone . Esmolol alone and
famotidine plus esmolol depressed contractility relative to values
with placebo or famotidine alone . The change in Vcf values was
similar for esmolol alone and for famotidine plus esmolol . establish-
ing that famolidine had no negative inotropic clfect in this subject
when cardiac reflex sympathetic action was eliminated as a con-
founding variable .
I .I I	-
o-o-remollmne
	-•=Pamoeame.esm
p--p=Placcba
A--•=Esmolol
300
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F
F+E
<5.05
<0 .05
c0.001
<0.01
<0.001
<0.002
<0 .001
<0 .01
241 x 0.28
common to all four of the o, - Vcfe
lines
. A similar
evaluative process was performed far each subject. For the
group, the average end-systolic stress used for comparative
purpose was 193 ± 18 g/cm2.
Placebo versus famotidine (Fig . 4A). The Vcfe for famo-
tidine (0.97 ± 0 .10
circumferences/s)
did not differ from the
value acquired for placebo (0 .97 ± 0 .09 circumferences/s).
The average AM, for famotidine was 0.006 ± 0 .013 cir-
cumferencesls above the placebo line (p = 0.14). The
shaded area of this and all other panels of Figures 4 and 5
delineates the AVcf values at x0
.02 circumferencesls from
the reference line . This deviation represents the potential
error of the method for any individual subject (19). Data for
9 of the 10 placebo versus famotidine comparisons fell within
these limits
: the remaining data point was slightly above the
limits .
Placebo versus esmolol (Fig. 4B). The Vcf, for esmolol
(0.89 x 0 .09 circumferencesls) was lower (p < 0 .001) than
the value for placebo. The average AVcf, for esmolol was
0 .076 = 0.013 circumferencesls below the placebo line (p <
0.001) . All data points were well outside the ±0.02 circum-
ferences/s limits .
Famotidine versus far oootidiae plus esmolol (Fig . SA). The
Me for famotidine pills esmolol was 0 .90'- 0.09 circumfer-
ences/s . This value differed significantly (p < 0
.001) from the
value for famotidine alone. The average AVcf, for famoti-
dine plus esmolol was 0 .077 ± 0.013 circumferencesls below
th-
'
motidine line (p < 0 .001) . All data points were well
.-.:-de the ±0.02 circumferences/s limits .
P PeE
Mean ram Ibe;ls/rninl 61 '- 8 57 0 6
Pressures (mm Hg)
LV peak systolic 112 • 9 115 0 8
LV end.systolic 95 x 11 99 2 8
Ao diastolic 56'- 8 59 2 7
Ao mean 83 3 86 t 5
LV preload
D0 (cm) 4 .89 0 0 .34 4.97 x 0.39
LV afterload
TVR Idynec-e cm
`I 1157 t 220 1,479 * 214
ar, (81000 139 24 163 '- 16
Overall LV systolic performance
D,, (cm)
3 .29
- 0.32 3 . 54 9 0 .31
%AD
32.9`-3.5
28 .9-2 .7
Vef lcircumferenceslsl 1
.04 x 0.09 0.93 2
0
.09
SV I (cm'Ime BSA) 48 *- 5
44 x 4
C1 (cm'lm' BSAI 2.83 s 0 .26 2.49
0
0.25
P Values
FoE
P P+E
F
F~+E
P
P+E
57 n 6 '20 .05 <0 .01
113 x 7
99_6
6'-_6
97 x 8 =0.07
4.96 o O.41 =0 .06
1537 x 273 '20.001
IMI x 14 <3.01
3
.49!0
.30
<0
.001
29 .6 x 2.7 <0 .00
994 -008 <0 .001
43 x 6
<0 .001
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Figure 4. Change in rate-corrected velocity of fiber shortening
(AVcf) in individual patients for placebo versus famotidine (panel
A) and placebo versus esmolol (panel B) determined at common
levels of left ventricular circumferenlial end-systolic wall stress . The
shaded areas represent the potential error of the method relative to
the reference line . See text for more detailed explanation, circ =
circumferences.
• p ( 001
Esmolol versus famotidine plus esmolol (Fig. 5B). The
Vcf, values for famotidine plus esmolol and esmolol were
similar (p
- 0 .90). The average AVef for famotidine plus
esmolol was 0.005 ± 0 .009 circumferences/s above the
esmolol line (p = 0 .21) . All data points were within the ±0 .02
circumferences/s limits .
Discussion
Hemodynamic effects of H 2 receptor blockade
. In this
clinical study, the direct and indirect effects of H 2 receptor
blockade on myocardial mechanics and contractility were
assessed
. By increasing blood pressure with the pure alpha,
agonist methoxamine, it was possible to compare data at
common left ventricular loading conditions in a given patient
regardless of whether famotidine, placebo or the rapidly
acting beta-blocker esmolol was administered . This protocol
had the unique feature that it allowed analysis of data with
the cardiac sympathetic nervous system intact as well as
pharmacologically ablated . Within this framework, there
was no evidence that circulating blood histamine contributes
to basal left ventricular contractile tone . All measurements
of overall left ventricular systolic performance were similar
[AI °° I
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Figure 5. Change in rate-corrected velocity of fiber shortening
(AVe f) with famotidine alone versus famotidine plus esmolol (panel
A) and esmolol alone versus famotidine plus esmolol (panel BI for
each subject determined at common levels of left ventricular cir-
cumferential end-systolic wall stress. The shaded areas represent the
potential error of the method relative to the reference line . See text
for more detailed explanation .
forr placebo and famotidine data . The only hemodynamic
effe2i of famotidine that approached statistical significance
was a 3-beat/min decrease in heart rate compared with that
obiained with placebo . This is similar to the previously
reported cardiac slowing effect of orally administered cimet-
idine and ranitidine (5,31,32) .
Comparisons with previous studies . How can one account
for the disparity in conclusions between the current data and
the studies of Kirch and Hinrichsen and coworkers (10,11)?
The famotidine dosage, route of administration and dosing
schedule as well as the study groups cannot be the explana-
tion because they were comparable in all three investiga-
tions . The most feasible explanation lies in differences in the
hemodynamic variables evaluated and the inherent limita-
tions of the methodologies used . In the studies of Kirch and
Hinrichsen et al. (10,11), nonspecific indexes of overall left
ventricular performance were employed. Systolic time inter-
vals showed an increase in the ratio of preejcction period to
left ventricular ejection time
. However, values for this ratio
vary widely in normal subjects (33,34) and are dependent
upon multiple factors including daily variations in left ven-
tricular stroke volume, preload, and afterload (33,35)
. Sim-
ilarly, their observation that left ventricular stroke volumes
determined by impedance cardiography decreased with fa-
motidine should he assessed critically . The scientific basis
for this technique, which records changes in the electrical
IACC Vat. 19. Nn.6
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impedance of the thoracic cavity with blood flow, is not
fully
understood (36,37). However, it is generally accepted That
the accuracy of stroke volume estimates by impedance
cardiography is dependent on many factors including the
subject's body size, muscle to fat content ratio, blood
resistivity, valvular competence and thoracic shape and
composition (37,38) .
In contrast, the present randomized, placebo-controlled
study used standardized echocardiographic and external
pulse tracing techniques to generate preload- and heart
rate-independent indexes
of myocardial contractile state
measured at common levels of left ventricular afterload
with and without beta-adrenoceptor blockade . This experi-
mental design eliminated left ventricular load, cardiac fre-
quency and reflex sympathetic responses as possible con-
founding variables
. Thus, while the cause for the differences
in conclusions between our data and those of Kirch and
Hierichsen et aL (10,11) cannot be specifically defined. the
current study more closely approximates the experimental
ideal of controlling as many physiologic variables as is
feasible . Furthermore, the results from our investigation are
in agreement with the large clinical experience which sug-
gests that histamine H, antagonists are hetnodynamically
benign in patients with a wide variety of cardiovascular
abnormalities.
Conclusions. Neither circulating blood histamine nor H,
receptor blockade has a significant impact on basal left
ventricular contractile state in humans .
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